T cells: Unexpected players in the bone loss induced by estrogen deficiency and in basal bone homeostasis

Annals of the New York Academy of Sciences

Volumn 1116, Issue , 2007, Pages 360-375

  Weitzmann, M Neale ^a   Pacifici, Roberto ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

B cells; Bone loss; Estrogen; Osteoclast; T cells; TNF

Indexed keywords

4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; CD40 LIGAND; CYCLOSPORIN A; OSTEOPROTEGERIN; SEX HORMONE; TUMOR NECROSIS FACTOR;

AGING; CELL STIMULATION; CONFERENCE PAPER; ESTROGEN DEFICIENCY; HUMAN; IMMUNE SYSTEM; IMMUNOCOMPETENT CELL; LYMPHOCYTE ACTIVATION; LYMPHOCYTE FUNCTION; MENOPAUSE; NONHUMAN; OSTEOLYSIS; OSTEOPOROSIS; OVARIECTOMY; T LYMPHOCYTE;

EID: 37249045914     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1196/annals.1402.068     Document Type: Conference Paper

References (75)

1. SUN, L., Y. PENG, A.C. SHARROW, et al. 2006. FSH directly regulates bone mass. Cell 125: 247-260.
2. IQBAL, J., L. SUN, T.R. KUMAR, et al. 2006. Follicle-stimulating hormone stimulates TNF production from immune cells to enhance osteoblast and osteoclast formation. Proc. Natl. Acad. Sci. USA 103: 14925-14930.
3. MANOLAGAS, S.C., S. KOUSTENI & R.L. JILKA. 2002. Sex steroids and bone. Recent Prog. Horm. Res. 57: 385-409.
4. PFEILSCHIFTER, J., R. KODITZ, M. PFOHL & H. SCHATZ. 2002. Changes in proinflammatory cytokine activity after menopause. Endocr. Rev. 23: 90-119.
5. HOFBAUER, L.C., S. KHOSLA, C.R. DUNSTAN, et al. 2000. The roles of osteoprotegerin and osteoprotegerin ligand in the paracrine regulation of bone resorption. J. Bone Miner. Res. 15: 2-12.
6. SUDA, T., N. TAKAHASHI, N. UDAGAWA, et al. 1999. Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families. Endocr. Rev. 20: 345-357.
7. ROGGIA, C., Y. GAO, S. CENCI, et al. 2001. Up-regulation of TNF-producing T cells in the bone marrow: a key mechanism bywhich estrogen deficiency induces bone loss in vivo. Proc. Natl. Acad. Sci. USA 98: 13960-13965.
8. AMMANN, P., R. RIZZOLI, J.P. BONJOUR, et al. 1997. Transgenic mice expressing soluble tumor necrosis factor-receptor are protected against bone loss caused by estrogen deficiency. J. Clin. Invest. 99: 1699-1703.
9. KIMBLE, R., S. BAIN & R. PACIFICI. 1997. The functional block of TNF but not of IL-6 prevents bone loss in ovariectomized mice. J. Bone Min. Res. 12: 935-941.
10. PACIFICI, R., C. BROWN, E. PUSCHECK, et al. 1991. Effect of surgical menopause and estrogen replacement on cytokine release from human blood mononuclear cells. Proc. Natl. Acad. Sci. 88: 5134-5138.
11. RALSTON, S.H. 1994. Analysis of gene expression in human bone biopsies by polymerase chain reaction: evidence for enhanced cytokine expression in postmenopausal osteoporosis. J. Bone Miner. Res. 9: 883-890.
12. KITAZAWA, R., R.B. KIMBLE, J.L. VANNICE, et al. 1994. Interleukin-1 receptor antagonist and tumor necrosis factor binding protein decrease osteoclast formation and bone resorption in ovariectomized mice. J. Clin. Invest. 94: 2397-2406.
13. KIMBLE, R.B., S. SRIVASTAVA, F.P. ROSS, et al. 1996. Estrogen deficiency increases the ability of stromal cells to support murine osteoclastogenesis via an interleukin-1 and tumor necrosis factor- mediated stimulation of macrophage colony-stimulating factor production. J. Biol. Chem. 271: 28890-28897.
14. RALSTON, S.H., S.J. GALLACHER, U. PATEL, et al. 1990. Use of bisphosphonates in hypercalcaemia due to malignancy [letter]. Lancet 335: 737.
15. SHANKER, G., M. SORCI-THOMAS & M.R. ADAMS. 1994. Estrogen modulates the expression of tumor necrosis factor alpha mRNA in phorbol ester-stimulated human monocytic THP-1 cells. Lymphokine. Cytokine. Res. 13: 377-382.
16. CHAUDHARY, L.R., T.C. SPELSBERG & B.L. RIGGS. 1992. Production of various cytokines by normal human osteoblast-like cells in response to interleukin-β and tumor necrosis factor-α: lack of regulation by 17β-estradiol. Endocrinology 130: 2528-2534.
17. ABRAHAMSEN, B., V. SHALHOUB, E.K. LARSON, et al. 2000. Cytokine RNA levels in transiliac bone biopsies from healthy early postmenopausal women. Bone 26: 137-145.
18. CENCI, S., M.N. WEITZMANN, C. ROGGIA, et al. 2000. Estrogen deficiency induces bone loss by enhancing T-cell production of TNF-alpha. J. Clin. Invest. 106: 1229-1237.
19. ABRAHAMSEN, B., K. BENDTZEN & H. BECK-NIELSEN. 1997. Cytokines and T-lymphocyte subsets in healthy post-menopausal women: estrogen retards bone loss without affecting the release of IL-1 or IL- 1ra. Bone 20: 251-258.
20. DI ROSA, F. & R. PABST. 2005. The bone marrow: a nest for migratory memory T cells. Trends Immunol. 26: 360-366.
21. CLARK, P. & D.E. NORMANSELL. 1990. Phenotype analysis of lymphocyte subsets in normal human bone marrow. Am. J. Clin. Pathol. 94: 632-636.
22. DI ROSA, F. & A. SANTONI. 2002. Bone marrow CD8 T cells are in a different activation state than those in lymphoid periphery. Eur. J. Immunol. 32: 1873-1880.
23. AHUJA, S.S., S. ZHAO, T. BELLIDO, et al. 2003. CD40 ligand blocks apoptosis induced by tumor necrosis factor alpha, glucocorticoids, and etoposide in osteoblasts and the osteocyte-like cell line murine long bone osteocyte-Y4. Endocrinology 144: 1761-1769.
24. FEUERER, M., P. BECKHOVE, N. GARBI, et al. 2003. Bone marrow as a priming site for T-cell responses to blood-borne antigen. Nat. Med. 9: 1151-1157.
25. TRIPP, R.A., D.J. TOPHAM, S.R. WATSON & P.C. DOHERTY. 1997. Bone marrow can function as a lymphoid organ during a primary immune response under conditions of disrupted lymphocyte trafficking. J. Immunol. 158: 3716-3720.
26. BERLIN-RUFENACH, C., F. OTTO, M. MATHIES, et al. 1999. Lymphocyte migration in lymphocyte function-associated antigen (LFA)-1-deficient mice. J. Exp. Med. 189: 1467-1478.
27. KONI, P.A., S.K. JOSHI, U.A. TEMANN, et al. 2001. Conditional vascular cell adhesion molecule 1 deletion in mice: impaired lymphocyte migration to bone marrow. J. Exp. Med. 193: 741-754.
28. DI ROSA, F. & A. SANTONI. 2003. Memory T-cell competition for bone marrow seeding. Immunology 108: 296-304.
29. MAZO, I.B., M. HONCZARENKO, H. LEUNG, et al. 2005. Bone marrow is a major reservoir and site of recruitment for central memory CD8+ T cells. Immunity 22: 259-270.
30. EFFROS, R.B. 2004. Replicative senescence of CD8 T cells: effect on human ageing. Exp. Gerontol. 39: 517-524.
31. FEUERER, M., P. BECKHOVE, Y. MAHNKE, et al. 2004. Bone marrow microenvironment facilitating dendritic cell: CD4 T cell interactions and maintenance of CD4 memory. Int. J. Oncol. 25: 867-876.
32. CENCI, S., G. TORALDO, M.N. WEITZMANN, et al. 2003. Estrogen deficiency induces bone loss by increasing T cell proliferation and lifespan through IFN-gamma-induced class II transactivator. Proc. Natl. Acad. Sci. USA 100: 10405-10410.
33. ROBEY, E.A., F. RAMSDELL, J.W. GORDON, et al. 1992. A self-reactive T cell population that is not subject to negative selection. Int. Immunol. 4: 969-974.
34. RAMMENSEE, H.G., K. FALK & O. ROTZSCHKE. 1993. Peptides naturally presented by MHC class I molecules. Annu. Rev. Immunol. 11: 213-244.
35. GROSSMAN, Z. & W.E. PAUL. 2000. Self-tolerance: context dependent tuning of T cell antigen recognition. Semin. Immunol. 12: 197-203; discussion 257-344.
36. TANCHOT, C., F.A. LEMONNIER, B. PERARNAU, et al. 1997. Differential requirements for survival and proliferation of CD8 naive or memory T cells. Science 276: 2057-2062.
37. BOSS, J.M. & P.E. JENSEN. 2003. Transcriptional regulation of the MHC class II antigen presentation pathway. Curr. Opin. Immunol. 15: 105-111.
38. GAO, Y., F. GRASSI, M.R. RYAN, et al. 2007. IFN-gamma stimulates osteoclast formation and bone loss in vivo via antigen-driven T cell activation. J. Clin. Invest. 117: 122-132.
39. AN, J., R.C. RIBEIRO, P. WEBB, et al. 1999. Estradiol repression of tumor necrosis factor-alpha transcription requires estrogen receptor activation function-2 and is enhanced by coactivators. Proc. Natl. Acad. Sci. USA 96: 15161-15166.
40. SHEVDE, N.K., A.C. BENDIXEN, K.M. DIENGER & J.W. PIKE. 2000. Estrogens suppress RANK ligand-induced osteoclast differentiation via a stromal cell independent mechanism involving c-Jun repression. Proc. Natl. Acad. Sci. USA 97: 7829-7834.
41. GALIEN, R. & T. GARCIA. 1997. Estrogen receptor impairs interleukin-6 expression by preventing protein binding on the NF-kappaB site. Nucleic Acids Res. 25: 2424-2429.
42. MUEGGE, K. & S. DURUM. 1990. Cytokines and transcription factors. [Review]. Cytokine 2: 1-8.
43. YANG, N.N., M. VENUGOPALAN, S. HARDIKAR & A. GLASEBROOK. 1996. Identification of an estrogen response element activated by metabolites of 17β-estradiol and raloxifene. Science 273: 1222-1225.
44. GAO, Y., W.P. QIAN, K. DARK, et al. 2004. Estrogen prevents bone loss through transforming growth factor beta signaling in T cells. Proc. Natl. Acad. Sci. USA 101: 16618-16623.
45. WEITZMANN, M.N., C. ROGGIA, G. TORALDO, et al. 2002. Increased production of IL-7 uncouples bone formation from bone resorption during estrogen deficiency. J. Clin. Invest. 110: 1643-1650.
46. RYAN, M.R., R. SHEPHERD, J.K. LEAVEY, et al. 2005. An IL-7-dependent rebound in thymic T cell output contributes to the bone loss induced by estrogen deficiency. Proc. Natl. Acad. Sci. USA 102: 16735-16740.
47. LINDBERG, M.K., J. SVENSSON, K. VENKEN, et al. 2006. Liver-derived IGF-I is permissive for ovariectomy-induced trabecular bone loss. Bone 38: 85-92.
48. HUANG, M., S. SHARMA, L.X. ZHU, et al. 2002. IL-7 inhibits fibroblast TGF-beta production and signaling in pulmonary fibrosis. J. Clin. Invest. 109: 931-937.
49. DUBINETT, S.M., M. HUANG, S. DHANANI, et al. 1995. Down-regulation of murine fibrosarcoma transforming growth factor-beta 1 expression by interleukin 7. J. Natl. Cancer Inst. 87: 593-597.
50. GIULIANI, N., S. COLLA, R. SALA, et al. 2002. Human myeloma cells stimulate the receptor activator of nuclear factor-kappa B ligand (RANKL) in T lymphocytes: a potential role in multiple myeloma bone disease. Blood 100: 4615-4621.
51. VAN ROON, J.A., K.A. GLAUDEMANS, J.W. BIJLSMA & F.P. LAFEBER. 2003. Interleukin 7 stimulates tumour necrosis factor alpha and Th1 cytokine production in joints of patients with rheumatoid arthritis. Ann. Rheum. Dis. 62: 113-119.
52. DE BENEDETTI, F., M. MASSA, P. PIGNATTI, et al. 1995. Elevated circulating interleukin-7 levels in patients with systemic juvenile rheumatoid arthritis. J. Rheumatol. 22: 1581-1585.
53. JOHN, V., J.M. HOCK, L.L. SHORT, et al. 1996. A role for CD8+ T lymphocytes in osteoclast differentiation in vitro. Endocrinology 137: 2457-2463.
54. KIM, Y.G., C.K. LEE, S.S. NAH, et al. 2007. Human CD4+CD25+ regulatory T cells inhibit the differentiation of osteoclasts from peripheral blood mononuclear cells. Biochem. Biophys. Res. Commun. 357: 1046-1052.
55. ERNST, C.W., J.E. LEE, T. NAKANISHI, et al. 2007. Diminished forkhead box P3/CD25 double-positive T regulatory cells are associated with the increased nuclear factor-kappaB ligand (RANKL+) T cells in bone resorption lesion of periodontal disease. Clin. Exp. Immunol. 148: 271-280.
56. GRCEVIC, D., S.K. LEE, A. MARUSIC & J.A. LORENZO. 2000. Depletion of CD4 and CD8 T lymphocytes in mice in vivo enhances 1, 25- dihydroxyvitamin D(3)-stimulated osteoclast-like cell formation in vitro by a mechanism that is dependent on prostaglandin synthesis. J. Immunol. 165: 4231-4238.
57. GRCEVIC, D., I.K. LUKIC, N. KOVACIC, et al. 2006. Activated T lymphocytes suppress osteoclastogenesis by diverting early monocyte/macrophage progenitor lineage commitment towards dendritic cell differentiation through down-regulation of receptor activator of nuclear factor-kappaB and c-Fos. Clin. Exp. Immunol. 146: 146-158.
58. WEITZMANN, M.N., S. CENCI, L. RIFAS, et al. 2001. T cell activation induces human osteoclast formation via receptor activator of nuclear factor kappaB ligand-dependent and -independent mechanisms. J. Bone Miner. Res. 16: 328-337.
59. HORWOOD, N.J., V. KARTSOGIANNIS, J.M. QUINN, et al. 1999. Activated T lymphocytes support osteoclast formation in vitro. Biochem. Biophys. Res. Commun. 265: 144-150.
60. WEI, S., M.W. WANG, S.L. TEITELBAUM & F.P. ROSS. 2002. Interleukin-4 reversibly inhibits osteoclastogenesis via inhibition of NF-kappa B and mitogen-activated protein kinase signaling. J. Biol. Chem. 277: 6622-6630.
61. RIANCHO, J.A., M.T. ZARRABEITIA, G.R. MUNDY, et al. 1993. Effects of interleukin-4 on the formation of macrophages and osteoclast- like cells. J. Bone Miner. Res. 8: 1337-1344.
62. BIZZARRI, C., A. SHIOI, S.L. TEITELBAUM, et al. 1994. Interleukin-4 inhibits bone resorption and acutely increases cytosolic Ca2+ in murine osteoclasts. J. Biol. Chem. 269: 13817-13824.
63. ABU-AMER, Y. 2001. IL-4 abrogates osteoclastogenesis through STAT6-dependent inhibition of NF-kappaB. J. Clin. Invest. 107: 1375-1385.
64. TAKAYANAGI, H., K. OGASAWARA, S. HIDA, et al. 2000. T-cell-mediated regulation of osteoclastogenesis by signalling cross- talk between RANKL and IFN-gamma. Nature 408: 600-605.
65. WYZGA, N., S. VARGHESE, S. WIKEL, et al. 2004. Effects of activated T cells on osteoclastogenesis depend on how they are activated. Bone 35: 614-620.
66. KONG, Y.Y., U. FEIGE, I. SAROSI, et al. 1999. Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand. Nature 402: 304-309.
67. TORALDO, G., C. ROGGIA, W.P. QIAN, et al. 2003. IL-7 induces bone loss in vivo by induction of receptor activator of nuclear factor kappa B ligand and tumor necrosis factor alpha from T cells. Proc. Natl. Acad. Sci. USA 100: 125-130.
68. LI, Y., A. LI, X. YANG & M.N. WEITZMANN. 2007. Ovariectomy-induced bone loss occurs independently of B cells. J. Cell Biochem. 100: 1370-1375.
69. YASUDA, H., N. SHIMA, N. NAKAGAWA, et al. 1998. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc. Natl. Acad. Sci. USA 95: 3597-3602.
70. UDAGAWA, N., N. TAKAHASHI, H. YASUDA, et al. 2000. Osteoprotegerin produced by osteoblasts is an important regulator in osteoclast development and function. Endocrinology 141: 3478-3484.
71. LI, Y., G. TORALDO, A. LI, et al. 2007. B cells and T cells are critical for the preservation of bone homeostasis and attainment of peak bone mass in vivo. Blood 109: 3839-3848.
72. WEITZMANN, M.N., S. CENCI, J. HAUG, et al. 2000. B lymphocytes inhibit human osteoclastogenesis by secretion of TGFbeta. J. Cell Biochem. 78: 318-324.
73. YUN, T.J., P.M. CHAUDHARY, G.L. SHU, et al. 1998. OPG/FDCR-1, a TNF receptor family member, is expressed in lymphoid cells and is up-regulated by ligating CD40. J. Immunol. 161: 6113-6121.
74. O'BRIEN, C., Q. FU, L. MOMMSEN, et al. 2006. Osteoblasts are not the source of RANKL and OPG in bone but are required for maintenance of osteoclast function. J. Bone Miner. Res. 22: abstract.
75. WEITZMANN, M.N. & R. PACIFICI. 2006. Estrogen deficiency and bone loss: an inflammatory tale. J. Clin. Invest. 116: 1186-1194.